CervoMed selects 50mg TID neflamapimod dose for Phase 3 DLB trial after Phase 1 PK study

CervoMed Inc.

Phase 1 healthy volunteer study completed evaluating PK of a new stable crystal form of neflamapimod.
Selected 50mg three times per day (TID) as dosing regimen for planned Phase 3 dementia with Lewy bodies trial.
PK profile of 40mg stable crystal form largely overlaps with therapeutically active DP Batch B from Phase 2b extension.
Dose increased to 50mg TID to ensure plasma drug concentrations match those of the active batch.
New controlled manufacturing process produces only stable crystal form, mitigating prior polymorph conversion issues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.